February 23, 2022
A Brooklyn federal judge on Wednesday granted the U.S. Securities and Exchange Commission's request to permanently bar Martin Shkreli from serving as an officer or director of any publicly traded company, piling onto a lifetime pharmaceutical industry ban the incarcerated former executive received last month.
April 02, 2021
Notorious, imprisoned pharma bro Martin Shkreli doesn't think he should be permanently barred from serving as a director or officer of a publicly traded company, and doesn't want to pay nearly $1.4 million in civil penalties in connection with U.S. Securities and Exchange Commission allegations he defrauded his former company Retrophin Inc.
April 01, 2021
Evan Greebel, the onetime Katten Muchin Rosenman LLP partner who was convicted of conspiring to commit fraud with disgraced former pharmaceutical executive Martin Shkreli, has reached a deal with the U.S. Securities and Exchange Commission that will settle its pending civil claims against him but won't require him to pay a fine.
March 22, 2016
The Brooklyn federal judge handling criminal allegations against Martin Shkreli and former Kaye Scholer LLP partner Evan Greebel stayed an overlapping civil fraud case Tuesday, rejecting the defendants' efforts to force prosecutors to litigate alongside the U.S. Securities and Exchange Commission but offering to set a criminal trial date soon.
February 26, 2016
Former Turing Pharmaceuticals AG CEO Martin Shkreli told the government that he has never intimidated witnesses and promised that he won’t do so if his civil securities fraud suit by the U.S. Securities and Exchange Commission is allowed to continue during his criminal trial.
February 18, 2016
The U.S. Securities and Exchange Commission took a shot at Evan Greebel on Thursday in its $7.5 million civil suit tied to the criminal fraud and conspiracy case against the Kaye Scholer LLP associate and pharma bad boy Martin Shkreli, saying Greebel is pushing for a "patently unfair" and "one-sided" discovery stay.
February 12, 2016
Ex-CEO Martin Shkreli and the Kaye Scholer LLP partner accused of committing securities fraud with him are fighting back against prosecutors’ bid to halt the U.S. Securities and Exchange Commission suit against them, saying the suit can’t wait for their criminal case.
January 26, 2016
Federal prosecutors have asked a New York judge to pause a securities fraud suit brought by the U.S. Securities and Exchange Commission against ex-CEO Martin Shkreli, saying the litigation should be put on the back burner while the criminal case against him proceeds.
January 04, 2016
A Delaware bankruptcy judge has given troubled pharmaceutical company KaloBios emergency permission to pay its employees, but barred any of that money going to fired CEO Martin Shkreli, who was charged with securities fraud two weeks before the company hit Chapter 11.
December 21, 2015
Martin Shkreli, who was recently arrested on charges of securities fraud and is widely known for jacking up the price of a drug used to treat AIDS symptoms, has been kicked out as CEO of KaloBios Pharmaceuticals Inc. and sued by investors in California federal court.